A Two-Part Single and Multiple Ascending Dose Trial of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LBT-3627 in Healthy Participants and in Participants With Parkinson's Disease.

Status:
RECRUITING

Trial end date:
2025-10-01

Target enrollment:

Participant gender:

Phase I a/b SAD/MAD study to evaluate safety and tolerability of LBT-3627 in both healthy volunteers and Parkinson's patients.

PHASE1

Longevity Biotech Australia Pty Ltd (subsidiary)

LBT-3627